Nisa Investment Advisors Reduces Johnson & Johnson Stake

Institutional investor sells over 288,000 shares of pharmaceutical giant

Apr. 3, 2026 at 9:37am

Got story updates? Submit your updates here. ›

An extreme close-up of the complex, interlocking machinery of a pharmaceutical production line, conveying the industrial scale and technical sophistication of the healthcare sector.An institutional investor's reduction in its Johnson & Johnson holdings reflects the volatility and uncertainty surrounding the pharmaceutical industry.New Brunswick Today

Nisa Investment Advisors LLC, an institutional investor, reduced its stake in Johnson & Johnson (NYSE: JNJ) by 30.2% in the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm sold 288,435 shares, leaving it with 665,946 shares of the pharmaceutical company's stock.

Why it matters

Johnson & Johnson is one of the largest and most influential pharmaceutical companies in the world, so changes in institutional ownership of its stock can provide insights into broader market trends and investor sentiment around the healthcare sector.

The details

Nisa Investment Advisors, which manages over $20 billion in assets, cited the sale of 288,435 JNJ shares as reducing its overall position in the company to approximately 2% of its investment portfolio. The firm continues to hold Johnson & Johnson as its 16th largest holding.

  • Nisa Investment Advisors made the share sale in the fourth quarter of 2025.
  • The 13F filing disclosing the transaction was submitted on April 3, 2026.

The players

Nisa Investment Advisors LLC

An institutional investment management firm that oversees over $20 billion in assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor changes in institutional ownership of major pharmaceutical stocks like Johnson & Johnson, as they can signal broader market trends.”

— Samantha Chen, Senior Equity Analyst

What’s next

Investors will be watching to see if other major institutional holders of Johnson & Johnson stock make similar adjustments to their positions in the coming quarters.

The takeaway

This transaction highlights the ongoing volatility and uncertainty in the healthcare sector, as large investors reevaluate their exposure to pharmaceutical giants like Johnson & Johnson.